April 15, 2022
1 minute watch
Disclosures: Swanson is employed by Eisai Inc.
Alzheimer’s disease patients who are treated with lecanemab have shown the potential to reaccumulate brain amyloid after drug withdrawal, said a speaker at the 2022 annual meeting of the American Academy of Neurology.
“Lecanemab produces a very robust reduction in brain amyloid with time and dose, and this correlates with slowing clinical decline,” Chad Swanson, Ph.D.executive director of the Neurology Business Group at Eisai Inc., said.
Lecanemab is being developed by Eisai and Biogen for patients with early AD.